{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:53:40Z","timestamp":1769180020295,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12325-020-01330-0","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T10:04:00Z","timestamp":1587463440000},"page":"2460-2476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Alicia","family":"Gayle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Schoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Raabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithwiraj","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"issue":"1","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1(1):15002.","journal-title":"Nat Rev Dis Primers"},{"issue":"10103","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"key":"1330_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/CLEP.S191418","volume":"11","author":"A Bergamasco","year":"2019","unstructured":"Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019;11:257\u201373.","journal-title":"Clin Epidemiol"},{"issue":"8","key":"1330_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s10067-018-4182-3","volume":"37","author":"JG Royle","year":"2018","unstructured":"Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA. The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol. 2018;37(8):2103\u201311.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1330_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","volume":"20","author":"V Cottin","year":"2019","unstructured":"Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019;20(1):13.","journal-title":"Respir Res"},{"issue":"9","key":"1330_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","volume":"14","author":"CP Denton","year":"2018","unstructured":"Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol. 2018;14(9):511\u201327.","journal-title":"Nat Rev Rheumatol"},{"issue":"26","key":"1330_CR7","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis\u2013associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"key":"1330_CR8","unstructured":"Boehringer Ingelheim GmbH. Ofev (nintedanib) capsules, for oral use. 2014 September 2019 [cited 2019 October 18]. https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf."},{"key":"1330_CR9","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. 2020 28 February 2020 [cited 2020 March 6]. https:\/\/www.boehringer-ingelheim.com\/press-release\/chmpopinionnintedanibssc-ild?v=."},{"issue":"1","key":"1330_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","volume":"20","author":"S Adler","year":"2018","unstructured":"Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease\u2014individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20(1):17.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1330_CR11","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"A-M Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold A-M, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;2(2):e71\u2013e83.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"1330_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.autrev.2017.09.010","volume":"16","author":"A Fischer","year":"2017","unstructured":"Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16(11):1147\u201354.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3899\/jrheum.170307","volume":"45","author":"A Fischer","year":"2018","unstructured":"Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement. J Rheumatol. 2018;45(2):235\u201341.","journal-title":"J Rheumatol"},{"issue":"5","key":"1330_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s12325-019-00929-2","volume":"36","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Fan Y, Thomason D, et al. Economic burden of illness among commercially insured patients with systemic sclerosis with interstitial lung disease in the USA: a claims data analysis. Adv Ther. 2019;36(5):1100\u201313.","journal-title":"Adv Ther"},{"key":"1330_CR15","unstructured":"NHS Digital. Read codes. 2018 [cited 2019 April 17]. https:\/\/digital.nhs.uk\/services\/terminology-and-classifications\/read-codes."},{"key":"1330_CR16","unstructured":"CALIBER. Code lists. 2019 [cited 2019 July 24]. https:\/\/www.caliberresearch.org\/portal\/codelists."},{"key":"1330_CR17","unstructured":"World Health Organization. International statistical classification of diseases and related health problems 10th revision. 2010 [cited 2019 April 17]. https:\/\/icd.who.int\/browse10\/2016\/en."},{"issue":"11","key":"1330_CR18","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"1330_CR19","unstructured":"UK Cabinet Office. NHS reference costs 2015 to 2016. 2019 [cited 2019 April 17]. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016."},{"issue":"12","key":"1330_CR20","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3899\/jrheum.120600","volume":"39","author":"DE Furst","year":"2012","unstructured":"Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. J Rheumatol. 2012;39(12):2303\u20139.","journal-title":"J Rheumatol"},{"issue":"8","key":"1330_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3899\/jrheum.180445","volume":"46","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Fan Y, Tang W, et al. Economic burden among commercially insured patients with systemic sclerosis in the United States. J Rheumatol. 2019;46(8):920\u20137.","journal-title":"J Rheumatol"},{"issue":"1","key":"1330_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/art.24086","volume":"61","author":"S Bernatsky","year":"2009","unstructured":"Bernatsky S, Hudson M, Panopalis P, et al. The cost of systemic sclerosis. Arthritis Care Res (Hoboken). 2009;61(1):119\u201323.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"1330_CR23","doi-asserted-by":"publisher","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS ONE. 2016;11(10):e0163894.","journal-title":"PLoS ONE"},{"issue":"7","key":"1330_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1330_CR25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1330_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1330_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1330_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","volume":"15","author":"ER McGrath","year":"2018","unstructured":"McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics. 2018;15(4):976\u201394.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1330_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","volume":"17","author":"A Oldroyd","year":"2017","unstructured":"Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies\u2014a guide to subtypes, diagnostic approach and treatment. Clin Med (Northfield Il). 2017;17(4):322\u20138.","journal-title":"Clin Med (Northfield Il)"},{"issue":"Suppl 5","key":"1330_CR30","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/rheumatology\/kex196","volume":"56","author":"UA Walker","year":"2017","unstructured":"Walker UA, Clements PJ, Allanore Y, et al. Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology. 2017;56(Suppl 5):v38\u2013v44.","journal-title":"Rheumatology"},{"issue":"3","key":"1330_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01330-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01330-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T01:14:24Z","timestamp":1618967664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01330-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01330-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}